Alida Biosciences Launched EpiPlex Platform in 2025
The platform enables simultaneous detection of three key RNA modifications in degraded clinical samples.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Will advancements in epitranscriptomics technology lead to more effective personalized medical treatments for patients?
In 2025, Alida Biosciences launched the EpiPlex platform, a system designed to detect, localize, and quantify three specific RNA modifications. This technology is capable of processing sparse and highly-degraded RNA from clinical samples.
Why it matters
By analyzing these RNA modifications, researchers can build more accurate models that link transcriptomic changes to patient phenotype. This field of epitranscriptomics aims to refine patient stratification and improve the predictability of therapeutic responses.
The EpiPlex platform detects N6-methyladenosine, inosine, and pseudouridine simultaneously. It processes these markers using a one-pot detection workflow.
The players
Alida Biosciences
A biotechnology firm that develops platforms for analyzing RNA modifications and epitranscriptomic data.
STORM Therapeutics
A drug discovery company specializing in small molecule therapies that target RNA-modifying enzymes.
Gudrun Stengel
The founder of Alida Biosciences who established the company five years ago.
The details
The platform utilizes a one-pot detection process—a method where multiple chemical reactions occur in a single reaction vessel—to analyze RNA modifications without excessive sample manipulation. Alida Biosciences integrates this data with gene expression profiles using machine learning models to map how these chemical changes influence biological outcomes. This allows for the analysis of highly-degraded RNA, which is often difficult to profile with standard sequencing techniques.
Timeline
2021: Gudrun Stengel founded Alida Biosciences.
2025: Alida Biosciences launched the EpiPlex platform.
The Tech Race
Epitranscriptomics is currently transitioning from basic research to a standard diagnostic layer in precision medicine. Alida Biosciences sits at the center of this race to integrate RNA modification data into AI models of biology.
The technology is currently being used to advance clinical drug development, including a Phase II trial for a drug targeting the methyltransferase-like 3 enzyme. Researchers should watch for upcoming releases of the EpiScout analysis software as it becomes more widely integrated into workflows.
The takeaway
RNA modifications are increasingly viewed as essential data for understanding therapeutic responses and patient stratification. Researchers should track future updates to the EpiScout software as a key indicator of the company's progress in standardizing these datasets.
What happens next
Alida Biosciences is currently collaborating with STORM Therapeutics on a Phase II drug that targets the methyltransferase-like 3 enzyme.
Further reading
Learn more about the latest innovations in Biotech research and clinical applications.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Will advancements in epitranscriptomics technology lead to more effective personalized medical treatments for patients?
